BMS Sighs In Relief As Opdivo Returns To Sales Growth

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.

Bristol-Myers-Squib_685347493_1200.jpg
BMS reports 16% year-over-year sales growth for Q2 2021

Bristol Myers Squibb Company was able to highlight some key positives for its immuno-oncology business in releasing its second quarter sales and earnings on 28 July, chiefly that its PD-1 checkpoint inhibitor Opdivo (nivolumab) has returned to growth after a pandemic-related decline and that prospects look good for adding new checkpoint inhibitor classes. But there are negatives as well – in the form of the failure of Opdivo plus Yervoy (ipilimumab) in gastric cancer and manufacturing issues for its CAR-T products

Opdivo posted 16% year-over-year sales growth, including 13% growth in US sales, as BMSunveiled a solid Q2 2021 earnings report...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.